Vaxart (OTCMKTS:VXRT) Posts Earnings Results

Vaxart (OTCMKTS:VXRT) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.04), Zacks reports. Vaxart had a return on equity of 53.04% and a net margin of 15.88%.

Vaxart Trading Down 7.5%

VXRT traded down $0.03 during midday trading on Thursday, hitting $0.37. The company’s stock had a trading volume of 434,774 shares, compared to its average volume of 288,712. The firm has a market cap of $90.17 million, a P/E ratio of 2.50 and a beta of 1.15. The firm has a 50-day moving average price of $0.46 and a two-hundred day moving average price of $0.58. Vaxart has a 52-week low of $0.33 and a 52-week high of $0.84.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Vaxart to a “hold” rating in a research report on Thursday, July 9th. One research analyst has rated the stock with a Hold rating. According to data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Vaxart Company Profile

Vaxart, Inc is a biotechnology company focused on developing oral recombinant vaccines delivered in tablet form. Its proprietary platform is designed to stimulate immune responses at mucosal surfaces, such as those in the nose and mouth, in addition to generating systemic immunity. The company’s approach is intended to offer a needle-free alternative to traditional injectable vaccines.

Vaxart’s development programs have included oral vaccine candidates for coronavirus infections, norovirus and influenza.